Bussiness3 months ago
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Akero Therapeutics Inc. — Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH — Presented...
